The Multi4 instrument integrates multiple functions into a single compact device. Local anesthesia is applied directly to the tumor, cancer tissue is precisely resected, and tissue samples are automatically transported out through the instrument and collected in a container for pathology analysis. The system also allows clinicians to stop bleeding and cauterize cancer tissue when needed. Unlike the current standard TURBT procedure, which requires a scheduled operation in an operating room with anesthesia, Multi4 treatment can be performed immediately upon detection during a routine office visit.

Miden Melle-Hannah, urologist and CEO of Multi4 Medical, described the CE mark as a historic milestone for the company and for European cancer care. “The Multi4 instrument integrates all necessary functions into a single compact device and is the first system where cancer tissue is automatically transported out through the instrument itself and captured in a container,” he said. “This makes treatment streamlined, safe, and feasible in an outpatient setting.”